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ABSTRACT 
 
The physico-chemical characterization, structure-pharmacokinetic and 
metabolism studies of new semi synthetic analogues of natural bile acids 
(BAs) drug candidates have been performed.  
Recent studies discovered a role of BAs as agonists of FXR and TGR5 
receptor, thus opening new therapeutic target for the treatment of liver 
diseases or metabolic disorders. Up to twenty new semisynthetic analogues 
have been synthesized and studied in order to find promising novel drugs 
candidates.  
In order to define the BAs structure-activity relationship, their main physico-
chemical properties (solubility, detergency, lipophilicity and affinity with serum 
albumin) have been measured with validated analytical methodologies. Their 
metabolism and biodistribution has been studied  in “bile fistula rat”, model 
where each BA is acutely administered through duodenal and femoral 
infusion and bile collected at different time interval allowing to define the 
relationship between structure and intestinal absorption and hepatic uptake 
,metabolism and systemic spill-over.  
One of the studied analogues, 6α-ethyl-3α7α-dihydroxy-5β-cholanic acid, 
analogue of CDCA (INT 747, Obeticholic Acid (OCA)), recently under 
approval for the treatment of cholestatic liver diseases, requires additional 
studies to ensure its safety and lack of toxicity when administered to patients 
with a strong liver impairment. 
For this purpose, CCl4 inhalation to rat causing hepatic decompensation 
(cirrhosis) animal model has been developed and used to define the 
difference of OCA biodistribution in respect to control animals trying to define 
whether peripheral tissues might be also exposed as a result of toxic plasma 
levels of OCA, evaluating also the endogenous BAs biodistribution. 
An accurate and sensitive HPLC-ES-MS/MS method is developed to identify 
and quantify all BAs in biological matrices (bile, plasma, urine, liver, kidney, 
intestinal content and tissue) for which a sample pretreatment have been 
optimized. 
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1. Introduction 
 
1.1 Natural Bile Acids 
 
BAs are acidic steroids, end products of cholesterol metabolism playing an 
important role in the homeostatic control of this molecule, representing the 
main pathway for its elimination from the body. 
Other BAs physiological functions are: 
• transport of lipids by forming mixed micelles which promotes intestinal 
absorption of the products of digestion; 
• stimulation of bile flow by osmotic mechanism; 
• complexing cations, such as Fe2+ and Ca2+, facilitating the intestinal 
absorption. 
Primary BAs are synthesized directly from cholesterol by the liver where 
they are conjugated with glycine and/or taurine and to a much less extent 
sulphated or glucuronide. The primary BAs are metabolized to secondary 
BAs by 7-dehydroxylation by intestinal bacteria. 
In humans, the main BAs in bile are glyco and tauro conjugated of the two 
primary BAs cholic acid (CA) and chenodeoxycholic acid (CDCA). A 
relatively high percentage up to 30-40% are secondary BAs, deoxycholic 
acid (DCA) and lithocholic acid (LCA), deriving respectively from CA and 
CDCA (Figure 1) by 7α-dehydroxylation.  
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Figure 1: principal human bile acid 
 
1.1.1 Chemical structure  
 
The BAs chemical structure (Figure 2) consists of two parts: the steroidal 
ring and the side chain. 
 Steroid ring: the typical chair conformation is due to the cis junction of 
the first two steroid rings (A and B), thus the hydrogen in C5 is in β 
position (β-BAs). 
In lower vertebrates, some BAs can have this junction trans [1a, 1b], so 
they are called 5α-BAs or Allo-BAs.  
As far as the hydroxyl positions, for natural BAs the most important are 
in 3α, 6α and 7α as deriving from cholesterol.  
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In trihydroxylated human BAs, the third hydroxyl group is in 12α 
position, but in other vertebrates there are other possible positions 
(C16 and C1). 
Regarding murine species, the third hydroxyl group can be also in 6β: 
these BAs are called muricholic acids [2]. 
BAs where one hydroxyl group is in configuration β rather than in α (or 
α instead of β) are defined as epimers. 
According the position the hydroxyl group could be differently oriented: 
axial or equatorial  
 Side chain: determines the main BAs classes according to the 
length, the terminal functional group (alcohols, sulphates or 
carboxyl) and substituents (usually hydroxyl groups).   
 
 
Figure 2: chemical structure of bile acids 
 
 
A 
B 
C D 
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1.1.2 Biosynthesis and metabolism 
 
The BAs biosynthesis from cholesterol is divided into two different 
pathways (Figure 3): the first classic (neutral), occurs in the hepatocyte 
and the second alternative (acidic), initiates in the liver and macrophages. 
In the classic pathway CYP7A1, cholic acid and chenodeoxycholic acid, 
the two primaries BA in humans, are formed.  
In the alternative pathway CYP27A1, mainly chenodeoxycholic acid is 
formed. 
 
 
 
 
 
Figure 3: bile acids biosynthesis 
CLASSIC  
NEUTRAL 
PATHWAY 
ALTERNATIVE 
ACIDIC 
PATHWAY 
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In the liver BAs are conjugated with glycine and taurine by BACs and BAT 
enzymes. 
In the intestine, there are regions full of bacteria (terminal ileum and 
caecum) where BAs are subjected to enzymatic reactions [3]:  
 side-chain deconjugation of glycine and taurine conjugated BAs by 
choloylglycine hydrolase;  
 oxidation of the hydroxyl groups in positions C3, C6, C7 and C12 to 
form oxo-derivatives by different bacterial dehydrogenases; 
 7α-dehydroxylation of primary BAs, CA and CDCA, to form the two 
main secondary BAs, in human, deoxycholic acid (DCA) and 
lithocholic acid (LCA). Usually, the 7α-dehydroxylase is less active 
for hydroxylated in 7β position [4] and has no effect on BAs 
conjugated with glycine or taurine [5]. 
 
 
1.1.3 Enterohepatic circulation   
 
The BAs biodistribution in humans is largely confined to the liver, bile, 
bowel and circulatory system [6] defined as enterohepatic circulation. 
In peripheral blood the BAs concentration is very low (µM level), about 
1000 times lower than that in the bile. Even in the liver, in physiological 
conditions, their concentration is very low as a result of a low residence 
time due to an efficient secretion into the bile. 
In blood, BAs are present mainly in the form of monomers partially bound 
to proteins (albumin).  
Enterohepatic circulation (Figure 4) of BAs is a dynamic entity in which the 
"pool" of BAs (their mass) constantly recirculates, realizing its 
physiological functions and undergoing synthesis processes as well as 
transformations at both hepatic and intestinal [7]. BAs have a first-pass 
hepatic uptake and they are secreted exclusively with bile; then they are 
absorbed efficiently in the ileum with an active mechanism, if conjugated 
with glycine and taurine and throughout the intestine by a passive 
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mechanism if free. Their elimination is mainly by faeces and the bacterial 
metabolites of some BAs absorbed, are relatively hepatotoxic. Metabolites 
as glucuronide and sulphates, are not absorbed because the transport is 
specific for ileal BAs conjugated with glycine or taurine and thank to their 
high hydrophilicity are not passively absorbed.  
These molecules can then perform their physiological function in the entire 
intestine before being absorbed in the terminal ileum. 
 
 
 
Figure 4: enterohepatic circulation 
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1.1.4 Receptorial activity (FXR and TGR5) 
 
Farnesoid X receptor (FXR), shown in Figure 5, is a negative feedback 
nuclear regulator in the BAs hepatic synthesis from cholesterol through the 
repression of cholesterol 7α-hydroxylase (CYP7A1), limiting step of the 
entire biosynthesis, conjugation and BAs transport of [6]. 
The membrane receptor TGR5 coupled to protein G [9] is expressed in gut 
cells specialized in the production of enteroendocrin hormones, controls 
secretion of glucagon-like peptide 1 (GLP-1), that controls the pancreas 
function and the regulation of sugar levels in the blood (Figure 5). 
 
Figure 5: Docking images of receptors FXR (left) and TGR5 (right) 
 
It has been demonstrated [10] that BAs are natural agonist for FXR or 
TGR5. In particular the primary BA chenodeoxycholic acid (CDCA) is the 
most important ligand for the first and cholic acid (CA) for the second, as 
shown in Table 1 [11]. Moreover lithocholic acid (LCA) is the more potent 
when in vitro data are generated but this secondary BA is present in low 
concentration representing not more than 5% of total bile acids pool. 
Table 1: activity values of natural bile acid for TGR5 and FXR 
BA 
TGR5** agonist potency FXR* agonist potency 
EC50 (µM) 
CDCA 30 13 
CA 40 NA 
LCA 0.58 20 
*AlphaScreen FXR **FRET (cAMP)NCL-H717 cells TGR5  
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1.2 Semi-synthetic bile acids 
 
1.2.1 Receptorial activity (FXR and TGR5) and therapeutic perspective 
  
In recent few years [12,13], a series of CDCA and CA semi synthetic 
analogues have been synthesized, in order to produce tools for the  
discovery new lead candidate more  potent and specific agonists for FXR 
or TGR5.  
New therapeutic targets for the treatment of cholestatic liver diseases like 
primary biliary cirrhosis (PBC), by acting on FXR, or diabetes, 
atherosclerosis and metabolic syndrome, by acting on TGR5 are highly 
demanded [14]. 
The two receptors differ in some amino residues, therefore it is possible to 
develop different BAs semi-synthetic derivatives with different selectivity 
for FXR or TGR5. 
In addition recent studies have shown that some of these new synthetic 
BAs are specific ligands for both receptors, opening new therapeutic 
opportunities for the contemporary treatment of cholestatic liver diseases 
and metabolic disorders as obesity, diabetes, dyslipidemia and metabolic 
syndrome [15]. 
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1.2.2 Structure-activity relationship 
 
It has been demonstrated [16, 17, 18], that small modifications in BAs 
structure modify their biological activity. For this reason it is necessary to 
accurately evaluate the relationship between structure and activity in 
particular the interaction with these receptors. 
About FXR, it has been showed [12] the existence of a small hydrophobic 
pocket, consisting on Phe284, Thr288, Leu451 and Phe461 residues 
(above in Figure 5), in which bile acids with alkyl group in 6α position could 
be hosted more easily. 
Moreover, glyco and tauro conjugates of this analogue could activate FXR 
too because of the largest pocket near the carboxylic group that could 
easily guest the glycine and taurine [19, 20]. 
About TGR5, the analysis of structure–activity relationship indicates some 
positions that are important for potency and selectivity for this receptor 
[21]: 
 Side chain length (if it is shorter reduces their potency on TGR); 
 substituent in C23-position of the side chain (i.e. (S)-methyl group 
increases potency and provides higher selectivity for TGR5 against 
FXR); 
 Bioisosters, substituents or groups with physical-chemical  and 
biological properties similar to carboxyl group, approach used in drug 
design to reduce toxicity or alter the metabolism of the reference 
compounds; 
 Number of hydroxyl groups (TGR5 shows a binding pocket with three 
hydrogen bond acceptors to anchor three hydroxyl groups of BA). 
 
Considering these informations, some examples of new BAs analogues 
with small structural modifications are reported in Table 2 and their 
respective receptorial activities are reported in Table 3. 
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Table 2: different structural modification of bile acid analogues 
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Table 3: activity values of synthetic bile acid for TGR5 and FXR 
 
BA 
TGR5**agonist potency FXR* agonist potency 
EC50 (µM) 
6α-ETHYL 
INT 747 15 0.15 
INT 777 0.9 175 
CARBOXYLIC 
UPF 2024 0.68 68 
UPF 2220 0.8 0.5 
UPF 2213 7.5 80 
FLUORIDE 
UPF 2304 0.34 0.2 
UPF 2227 22 2.9 
UPF 2207 1.5 4.3 
UPF 2226 7 5.6 
BIOISOSTERES 
UPF 2295 0.72 0.15 
UPF 2308 0.1 0.45 
UPF 2289 0.48 0.075 
UPF 2224 2 1 
UPF 2225 4 1.7 
SULPHATE-SULPHONATE 
INT 767 0.4 0.033 
UPF 2284 0.76 0.24 
UPF 2307 0.016 1.5 
UPF 2293 0.2 1.3 
UPF 2283 0.93 0.49 
UPF 2021 1.1 3 
UPF 2023 1.6 0.65 
*AlphaScreen FXR **FRET (cAMP)NCL-H717 cells TGR5 
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1.2.3 Obeticholic acid as potential novel drug 
 
The 6α-ethyl chenodeoxycholic acid (Figure 6), later became Obeticholic 
acid (OCA), is the most potent FXR agonist [12].  
 
 
Figure 6: chemical structure of Obeticholic acid (OCA) 
 
As previously reported, the presence of ethyl in 6α position allows to 
increase the activity in FXR dependent processes as therapeutic targets 
for human disease. 
It is the first semi-synthetic BA to be undergoing in human studies for 
specific liver and gastrointestinal disorders [22]. 
Moreover, it has been demonstrated [23, 24] its efficacy in primary biliary 
cirrhosis (PBC) treatment (ClinicalTrial.gov: http://www.clinicaltrials.gov 
NCT01473524), type 2 diabetes with non-alcoholic fatty liver disease 
(NAFLD), and non-alcoholic steatohepatitis (NASH) (ClinicalTrial.gov: 
http://www.clinicaltrials.gov NCT01265498).  
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1.3 Physico-chemical properties of natural and semi-synthetic BAs 
 
It is well know that most of the BAs biological properties can be explained 
and also predicted knowing their physico-chemical properties [25]. 
BAs are present in bile and intestinal content at mM level, so they can self-
aggregate to form micelles depending on their physical-chemical 
properties, as for common anionic detergents. Their structure and the 
number and position of hydroxyl groups, the length and substituent in the 
side chain play a major role in their amphipaticity and in the tendency to 
form aggregates at a given critical micellar concentration. 
The main physico-chemical properties in aqueous solution, including 
solubility, detergency, lipophilicity, and binding affinity with albumin) have 
been evaluated [25] on BAs as a protonated non-ionized species (bile 
acids) and ionized species (bile salts).  
 
1.3.1 pKa  
 
The BAs pKa plays the major role in determining the presence of 
protonated form in respect to the ionized one at a given pH (in vivo 
changes within the gastrointestinal tract)  
It has been demonstrated [26] that the pKa values for all common 
carboxylate bile acids is 5.00, as isopentanoic acid and this means that 
steroid ring substituents do not influence ionization. 
Therefore, at physiological pH > 5.00 (in hepatic bile pH is about 8.00), 
they are present in ionized form, i.e. as bile salts.  
The glycine and taurine conjugations lead to a lower of pKa of about 2.4 
and 5 units respectively, due to inductive effect of the amide bond on the 
carbonyl group. 
Taurine conjugated BAs have a pKa value about 0, because of the 
extremely acidic nature of the sulfonic acid group, and for this reason 
taurine conjugated BAs are fully ionized at all physiological pH. The 
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glycine conjugated with a pKa=3.6 are fully ionized only if the pH in 2 units 
higher than their pKa and vice versa at lower pH. 
 
1.3.2 Lipophilicity 
 
The lipophilicity is the BAs ability to distribute in a lipid domain (as lipidic 
cell membranes) and it is experimentally measured with the 1-
octanol/water partition coefficient, LogPo/w, that strongly depends on 
solution pH and molecule pKa.  
LogPo/w = LogDo/w + Log (1+10
pH-pKa), 
where distribution coefficient D is ratio between the total concentrations 
(protonated and ionized form) in the two phases and partition coefficient P 
is referred to a single chemical species. 
For in vitro experiments, 1-octanol is officially used as non polar solvent 
because of its similarity to cell membrane lipid layer and aqueous solution 
at physiological pH (about 7.20) is used to consider all BAs fully ionized. 
BAs that display some preference for the nonpolar phase (LogP > 1, as 
unconjugated BAs), are defined lipophilic or hydrophobic, while BAs are 
hydrophilic or lipophobic when LogP < 0 (as taurine conjugated). 
 
1.3.2 Water solubility 
 
BAs aqueous solubility is measured for the protonated non-ionized 
species (almost insoluble). When fully ionized BAs are usually much more 
soluble, the pKa and the solution pH play a major role in the monomer 
water solubility. 
BAs solubility is influenced by [26]: 
- steroidal ring substituents (number and orientation): high number or β-
orientation of hydroxyl group increase solubility; 
- side chain structure (length and substituent): shorter side chain or 
presence of sulphated or hydroxyl groups increase solubility. 
In vitro experiments are performing by solubility measurements at pH=1.00 
four units below the pKa of the common carboxylate BA (about 5.00) and 
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even when amidated with glycine (pKa= 3.9) order to consider only 
protonated species. For the taurine conjugate the protonated form cannot 
be produced having a very low pKa and therefore their solubility is that of 
the ionized form which on turn is not affected by the pKa. 
The BAs solubility and its variation with the pH are very important to define 
if the drug is present in solution in a given biological fluid and therefore 
suitable to be absorbed. In addition it is very important to evaluate the 
solubility at stomach pH (acid) when orally administration. 
 
1.3.3 Detergency 
  
BAs are amphipathic molecule with the steroid ring divided in two regions: 
the hydrophilic α face containing the 3α, 7α, 12α oriented hydroxyl groups 
and the hydrophobic β face (i.e. Cholic acid, Figure 6a) that lead to self-
association to form micelles via back to back interaction leaving the 
hydroxyl groups oriented toward the solution. Additional interactions with 
other dimers via hydrogen bound of the hydroxyl allow to increase the 
aggregation number step-wise. 
The hydrophobic/hydrophilic ratio determines the CMC and the micelles 
dimensions. The side chain play a minor role in the aggregates but usually 
the increased length reduces the CMC value. 
In respect to typical anionic detergents, BAs self-association occurs in a 
larger concentration range and it is more stepwise passing through dimers 
(i.e. Cholic acid, Figure 6b), tetramers and so on [27, 28].  
The concentration at which BAs begin to self-associate is called Critical 
Micellar Concentration (CMC).  
The methods used to calculate this parameter [29] consist of: 
-dynamic measurements of surface tension using maximum bubble 
pressure principle; 
-dye solubilization in BA solution and absorbance measures at the dye 
absorption wavelength. 
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The data previously obtained shows that the key factor influencing self-
association is the contiguous hydrophobic area (β face): any decrease in 
lipophilicity of this area increase the CMC values. 
As far as the side chain, a reduction in length decreases the CMC. 
Regarding the conjugation with glycine or taurine, this lead to small 
reduction of CMC values in respect to free BA: the polarity of the amide 
bond is compensated by the increased length of the side chain. 
Natural BAs possess relatively low CMC values (< 10 mM) because of the 
hydroxyl groups in the same surface (α orientation) and their negative 
charged side chain that facilitate the back-to-back micelles formation (i.e. 
Cholic acid, Figure 6b).  
For this reason, anionic form solubility (pH>7.00) increases because of the 
micelles formation and the consequent greater solubilization of the anionic 
forms inside the micelles.  
Indeed, another parameter also important is critical micellar pH (CMpH), 
that is the pH above which a solid BA dissolves in a micellar phase and 
depends directly on the pKa, the CMC and the solubility of the protonated 
form (pH=1.00).  
The CMpH value has a direct impact with intestinal and stomach 
processes: when a BA orally administrated passes from stomach (pH<3) 
to intestine, the absorption is promoted by a pH ≥ CMpH.  
For BAs administered in concentration higher than their CMC, this can be 
more easily verified after meal, when intestine pH increases. 
 
(a)      (b) 
 
Figure 6: Cholic acid monomer (a) and dimer with back to back self-association (b)  
7α 
3α 
12α 
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1.3.4 Affinity binding to serum albumin  
 
The affinity binding to serum albumin is an important parameter that plays 
a role in the systemic transport and also the bioavailability of BAs as drugs 
because it determines the percentage of BAs present in blood in a free 
unbound form, potentially more pharmacologically active. 
On the other hand, it has been previously demonstrated [30, 31, 32] that 
there is a receptor for albumin on the hepatocytes that could be 
responsible for the more efficient hepatic extraction of BAs when more 
bound to the albumin.  
The interaction of human serum albumin with BAs has been measured by 
equilibrium dialysis technique [31] and the affinity constant depends on: 
number of hydroxyl groups (decrease if they are less) and substitution of 
7α-hydroxyl group with 7-keto group.  
Furthermore, the unconjugated bile acids have binding constants higher 
than the conjugated forms [33, 34].  
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1.4 Bile fistula rat model  
  
The BAs structure-activity relationship as drugs need to be verified using 
suitable experimental animal models able to determine their 
pharmacokinetic and metabolism and predictive to human situation. 
For this reason, hepatic metabolism and biliary secretion have been 
evaluated using the animal model “bile fistula rat”, where the bile duct is 
cannulated in order to collect bile at different time interval during the acute 
administration by one hour infusion either intravenously and orally (id by 
gavage).  
During this study, plasma is also collected in order to evaluate the hepatic 
uptake and the systemic spillover. When possible at the end of the 
experiment the main target organs (liver, kidney, intestine tissue and 
content and stools) will be collected. 
This model consist on BA administration with intravenous and 
intraduodenal (by gavage) infusion (Figure 7), preferred over the single 
bolus because in the anesthetized animal, the intestinal motility is 
hampered so the infusion allows the progression of the substance.  
 
 
 
Figure 7: intraduodenal and intravenous infusion in bile fistula rat model 
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1.5 OCA in cirrhosis treatment: biodistribution and metabolism in vivo     
 
In previous studies carried out in bile fistula rat model [35] it has been 
demonstrated that the pharmacokinetic and metabolism of OCA is quite 
similar to CDCA  with the only exception that OCA is not 7-dehydroxylated 
by intestinal bacteria, but it is still conjugated with glycine and taurine in 
the liver.  
The overall physico-chemical and biological properties of OCA are 
comparable to the natural analogues in rat and therefore it is expected the 
same for humans. 
Recent clinical studies demonstrated the efficacy of OCA in the treatment 
of primary biliary cirrhosis (PBC), and high plasma levels of OCA and its 
glycine and taurine conjugate forms have been found in these patients. 
During cholestasis, OCA will increase in blood exactly like endogenous 
BAs as a result of the different compartmentalization in the enterohepatic 
circulation, caused by an impaired hepatic uptake or biliary secretion 
(cholestasis). 
OCA is not subjected to 7-dehydroxylation by enzyme 7α-dehydroxylase in 
intestinal bacteria because of the steric hindrance of 6 ethyl group. For this 
reason, OCA do not produce mono-hydroxylated BAs (such as lithocholic 
acid from CDCA) that are potentially toxic at high concentration; on the 
other hand the formation of mono-hydroxyl BAs (secondary BAs) is an 
excretory mechanism since they are the main constituents of BA stools. 
An appropriate balance between BA excretion and the feedback 
mechanism of their synthesis from cholesterol keeps the equilibrium in the 
overall enterohepatic circulation which drives the biodistribution of the 
endogenous BA and OCA, not only in bile but in almost all target organs 
including liver, the overall intestinal tract, blood, urine and stools. 
Any alteration in the physiology of the involved organs (due to a pathology, 
like cirrhosis) determines a different biodistribution among them, resulting 
in an increased concentration or accumulation in a given fluid, like blood in 
the specific case of liver impairment, because of a poor liver uptake. 
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For this reason it is necessary to achieve more accurate informations, 
predictive for human, regarding OCA biodistribution and metabolism in all 
the involved organs particularly in liver disease. 
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2. Aim and rationale 
 
Despite numerous studies on physico-chemical properties, metabolism, 
physiology and structure-activity relationship of endogenous BAs, many 
aspects have not yet been fully elucidated.  
This limitation is probably due to the complexity of the BA metabolism 
which is different in human and animal species. 
Indeed the high variability of BAs composition in different organs and the 
several metabolites produced in low concentrations could lead to analysis 
procedures very difficult and time consuming an often poor accurate and 
precise. 
Moreover, the recent discovery of BAs role as agonists of receptors FXR 
and TGR5 opens new therapeutic target for the treatment of cholestatic 
liver diseases, as primary biliary cirrhosis (PBC) and Nonalcoholic 
steatohepatitis (NASH), or metabolic disorders, as obesity, diabetes, 
dyslipidemia and metabolic syndrome. 
In this context, the collaboration with Prof. Roberto Pellicciari’s laboratory, 
(University of Perugia), Intercept Pharmaceuticals and Servier, has been 
set-up properly design new candidate BAs analogues for the discover of 
promising novel drugs. 
This research activity joined with this project by focusing on physico- 
chemical characterization and metabolic studies of new synthetic 
analogues of BAs with structural changes from cholic and 
chenodeoxycholic acid natural analogues. 
The rationale of this project is to design compounds that are active on the 
target receptors and in part more metabolically stable, such as resistant to 
intestinal bacterial 7-dehydroxylation responsible for the formation of 
potentially toxic metabolites. Moreover it is important to maintain an 
efficient hepatic uptake and intestinal absorption. 
In the last few years, up to twenty new synthetic analogues have therefore 
been synthesized and studied. 
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They can be divided into two main groups: unconjugated and steroid 
modified BAs and BAs conjugated with taurine or glycine or pseudo 
conjugates (sulphonate and sulphate analogue). 
The first group includes derivatives with modifies from CDCA or CA by 
introducing an ethyl group in 6α position and a substituent in 23 position 
(methyl, methoxyl, fluorine).  
These derivatives are selected according with their potency toward on 
FXR rather than TGR5 and on the mean time the increase of metabolic 
stability toward 7α-dehydroxylation and side chain conjugations. 
The second group consists on modifies in the terminal functional group of 
synthetic analogues side chain (sulphonate, sulphate or taurine 
conjugated), in order to have an efficient secretion of bile and high 
metabolic stability. 
The new BA analogues studied are: UPF 2024, UPF 2220, UPF 2213, 
UPF 2207, UPF 2226, UPF 2227, UPF 2304, UPF 2224, UPF 2225, UPF 
2295, UPF 2289, UPF 2308, UPF 2021, UPF 2023, UPF 2284, UPF 2283, 
UPF 2293, UPF2307. 
The results were compared with those obtained in previous years using 
the same experimental protocol in the laboratory of Professor Roda for 
endogenous BAs (CDCA, CA, TCDCA) and analogues INT-747, INT-767, 
INT-777.  
In order to achieve more accurate informations, predictive for human, 
regarding its biodistribution and metabolism, it would be necessary to 
develop an animal model causing cirrhosis with hepatic decompensation. 
Indeed, it should be evaluated the biodistribution and mass balance of 
OCA and its metabolites (taurine and glycine conjugates) in CCl4-induced 
decompensated cirrhotic rats after a single oral dose of 30 mg/kg, 
quantifying them in the biological fluids and organs. 
Aim of the study is to evaluate whether in decompensated liver disease, 
peripheral tissues (liver, kidney and intestine) might be also exposed as a 
result of toxic plasma levels of OCA due to porto-systemic shunting, liver 
metabolism impaired and cholestasis. 
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In addition, endogenous BA quali-quantitative composition in the studied 
biological fluids and organs has been quantified in order to ascertain the 
extent of biodistribution of these endogenous BA as a consequence of 
liver failure and to compare data with OCA and its metabolites in cirrhotic 
and control animals.  
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3. Materials and methods 
 
3.1 Materials and reagents 
 
All solvents are purchased from LiChrosolv® for HPLC, Merck (Darmstadt, 
Germania) with high purity analytical grade. Silica C18 cartridge for SPE 
(Isolute ®, 53 Å, 6mL) are purchased from StepBio S.r.l. (Bologna, Italy). 
Each semi-synthetic BA powder is synthesized and purified (purity>99 %) 
from group of Prof. R. Pellicciari (Institute of Pharmaceutical Chemistry, 
University of Perugia, Italy). 
 
3.2 HPLC-ESI-MS/MS method 
 
3.2.1 HPLC optimization parameters 
 
All samples are analyzed by liquid chromatography using Waters Alliance 
2695 system. The column used for BAs quantitative analysis is XSelect 
Phenyl-Hexyl CSH Column 5μm, 150x2.1 mm (protected with 
SecurityGuard Phenyl-Hexyl 2.1x10mm i.d. guard column) from Waters 
S.p.a. (Milano, Italy). 
Elution is performed at flow rate of 0.15 mL/min, sample injection volume 
is 5 μL and the column is maintained at 45°C. 
The elution gradient is optimized (see Table 4) with mobile phase using 
15mM ammonium acetate buffer (pH=8.00) as aqueous phase and 
acetonitrile:methanol, 75:25, v/v as organic phase.  
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Table 4: Elution gradient 
Time (min) A% B% Flow (mL/min) Curve 
0.00 65 35 0.150 1 
10.00 65 35 0.150 1 
10.30 55 45 0.150 6 
21.00 55 45 0.150 1 
21.30 0 100 0.150 6 
23.30 0 100 0.150 1 
24.00 65 35 0.150 6 
35.00 65 35 0.150 1 
 
This gradient allows to separate all the BAs studied as shown in Figure 8.  
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Figure 8: chromatograms of the BAs analyzed divided into carboxylic (A), fluorine 
substituted (B), bioisosters (C) and sulphates/sulphonates (D) 
 
The HPLC is coupled with electrospray source (ES) – triple quadrupole 
Mass Spectrometer with the following parameters. 
 
3.2.2 ES- Mass spectrometry optimization parameters 
 
The HPLC system was connected with Quattro-LC 9007 (MicroMass): 
triple quadrupole analyzer operating with an electrospray (ES) ionization 
source in negative mode. The following parameters (Table 5) are 
performed and optimized by direct infusion of each BA, using both single 
MS and tandem MS/MS configuration. 
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Table 5: Tuning parameters 
Instrument parameters Value 
Capillary 3. 
0 KV 
Cone 60 V 
Extractor 1 V 
RF lens 0.50 V 
Source block temp. 120°C 
Desolvation temp. 180°C 
MS 
Entrance 1.0 V 
Exit 10 V 
Ion energy 1.5 V 
LM resolution 12.0 
HM resolution 12.0  
MS2 
Ion energy 3.0 V 
LM resolution 12.0 
HM resolution 12.0 
Pressure 
Analyzer vacuum 3.4e-5 mBar 
Gas cell 2.6e-3 mBar 
Flows 
Nebulizer (Nitrogen) 87 l/h 
Desolvation gas (Nitrogen) 800 l/h 
Multiplier 650 V 
 
The acquisition mode used in this method is multiple reaction monitoring 
(MRM) mode. It allow to achieve more sensitivity and selectivity, in 
particular with isomers (BAs that have the same molecular weight but 
different specific fragmentation pattern) 
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For the qualitative analysis (identification of new entities) the acquisition 
mode single ion monitoring (SIM) is also used. 
MassLynx software version 4.0 is used for data acquisition and 
processing. 
Mass spectra of several semi-synthetic BAs standards (one of each 
principal group), obtained with tandem MS acquisition, are reported below 
(Figure 9). 
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Figure 9: mass spectra of the BAs analyzed divided into carboxylic (A), fluorine 
substituted (B), bioisosters (C) and sulphates/sulphonates (D) 
 
3.2.3 Method validation 
 
The limit of detection (LOD) of the different BAs (for each biological matrix) 
is calculated as three times signal-to-noise ratio and the limit of 
quantification (LOQ) as three times LOD.  
The LOQ values obtained for each BA for each matrix are between 0.005 
and 0.01μM and the LOD values were between 0.001 and 0.02 μM. 
In addition, intra-day and inter-day precision and accuracy are calculated 
for each BA by analyzing them in three different quality controls (QCs) 
corresponding low (0.3 μmol/l), medium (8.0 μmol/l) and high (17.5 μmol/l) 
representative concentrations. 
The internal standard concentration (1 μmol/l for OCA, G-OCA, T-OCA 
and 1μmol/l for INT-777, T-INT-777 and G-INT-777 when analyte is OCA) 
is constant in all the QCs. 
lntra-day and inter-day accuracy, measured as RME, ranged from 7.7% to 
8.0%. Precision, measured as CV (%), is below 10.0% and 9.4% for intra- 
and inter-day, respectively. 
The total recovery is determined as the ratio of the analyte in mobile 
phase directly injected with respect to the analyte in mobile phase injected 
after the clean-up procedure (previously described in 3.3) 
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The total recovery after pretreatment was about 95% for each analyte.  
The matrix effect of each biological matrix was calculated as the ratio of 
the analyte in mobile phase with respect to the analyte in the real sample 
(collected at time zero and diluted 1:10, v/v with mobile phase) fortified at 
the end of the clean-up.  
The average recovery due to the effect matrix for all analytes is 97% while 
for the internal standards are 100% (CV% < 2), thus confirming the 
absence of the matrix effect in optimized conditions. 
The calibration curves show good linearity in the range of concentration 
between 0.1and 20 μM, suitable to analyze all BAs in all biological 
matrices. In terms of linearity, the regression coefficients for all the 
calibration curves of the BA are higher than 0.992. 
Table 6 shows the parameters for the calibration curve derived from the 
statistical analysis of six calibration curves (in duplicate) obtained in 
mobile phase. 
 
Table 6: Calibration curve for some BAs representing the principal groups 
Bile Acid Intercept Slope R2 
OCA 2.74 e-3±0.07e-3 4.2e-1±0.1e-1 0.992±0.006 
UPF 2304  
(23-fluorine substituted) 
5.56e-4±0.09e-4 2.3e-4±0.05e-4 0.984±0.004 
UPF 2295 
(bioisoster) 
3.67e-3±0.07e-3 4.04e-2±0.08e-2 0.997±0.008 
UPF 2293 
(sulphonates) 
2.20e-3±0.06e-3 5.04e-2±0.08e-2 0.986±0.005 
UPF 2284 
(sulphates) 
2.40e-3±0.06e-3 4.03e-2±0.07e-2 0.997±0.008 
UPF 2220  
(shorter side chain) 
6.0e-4±0.1e-4 2.11e-1±0.05e-1 0.996±0.007 
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3.3 Physico-chemical properties  
 
3.3.1 pKa and lipophilicity 
 
The pKa values are calculated in silico for each semi-synthetic BA with 
Epik module version 2.2 from Schrödinger Suite 2010, with water as the 
solvent.  
Standard solution of each semi-synthetic BA is prepared dissolving about 
11 mg (MW =400-500 u) in 500µL NaCl 0.15 M to obtain a 50mM solution. 
For semi-synthetic bile acid with carboxylic group in the side chain, 
salification is done with an excess of NaHCO3 (1:1, mol : mol). 
The procedure [29] to measure the partition coefficient 1-octanol/water for 
(LogPA
-) is carried out for each BA using a 100µM solution with phosphate 
buffer 0.1 M pH= 8.00 (all BAs were full ionized at this pH value), 
previously saturated with 1-octanol. 
Then 2 mL of this solution is added to 2 mL of 1-octanol previously 
saturated with phosphate buffer 0.1 M pH= 8.00 and incubated at room 
temperature. 
After about one week, the mixture is centrifuged to have a clean 
separation of two immiscible phases. 
The buffer solution thus obtained is diluted in mobile phase and injected in 
HPLC-MS/MS system for bile acids quantification, as written below (in 
3.4). 1-octanol/water partition coefficient is expressed as logarithmic ratio 
of the concentrations: 
        
[  ]        [  ]     
[  ]     
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3.3.2 Water solubility 
 
The water solubility is determined only for semisynthetic BA having a 
carboxylic group in the side chain because their protonated forms (at 
pH<pKa-2) could be poor soluble.  
The sulphate and sulphonate analogues are highly water soluble being 
fully ionized at a pH range from 0 to 12. 
A small amount of each bile acid was suspended, without preliminary 
salification, in 5 mL of 0.1M HCl (pH about 1). After one week of 
incubation at 25 °C, the saturated solutions were filtered on a Millipore 
filter (0.22 μm) and then injected in HPLC-ES-MS/MS system for BA 
quantification, as reported below (in 3.4). Water solubility was expressed 
as concentration (μmol/l). 
 
3.3.3 Detergency 
 
The detergency was evaluated by surface tension (ST) measurements   
and dye solubilization technique [36] and the critical micellar concentration 
(CMC) was calculated. 
Standard solution of each semi-synthetic BA is prepared dissolving about 
11 mg (MW= 400-500 a.m.u.) in 500µL NaCl 0.15 M to obtain a 50mM 
solution. For semi-synthetic BA with carboxylic group in the side chain, 
salification is done with an excess of NaHCO3 (1:1, mol : mol). 
In the first method, the relationship between surface tension and BAs 
CMC is measured by an improved maximum bubble pressure method with 
a tensiometer (Sensadyne 6000, Chem-Dyne Research Corp., Milwaukee, 
WI) consisting of two glass probes connected to a source of compressed 
air. The bubble frequency was 1 bubble/sec in distilled water at room 
temperature (P=2.7 atm) and the calibration was made with water and 
methanol. 
The ST of each BA solution, as sodium salt, is measured at various 
concentrations between 50 mM and 0.1 mM with appropriate dilutions. 
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Then CMC values are calculated from the plot ST values versus logarithm 
of the BA concentration: the abscissa value corresponding to the point 
where the two regression lines (corresponding respectively to monomeric 
and micellar phase) intersect. 
The second method is based on the fact that some dyes, specifically 
Orange OT (purchased from Intercept Pharmaceuticals S.p.a., San Diego, 
CA), are almost insoluble in water but dissolve in solutions with micellar 
aggregates that incorporate them; thus, the absorbance of the solution 
due to the amount of the dye dissolved increases with BA concentration 
(after CMC achievement). The amount of dye solubilized in relation to BA 
concentration is determined with absorption spectroscopy.   
For each BA, various solutions at different concentrations, between 50 mM 
and 0.1 mM with appropriate dilutions, are incubated under stirring at room 
temperature for 3 days with an excess of Orange OT. Then all the 
solutions are centrifuged and filtered through a 0.22 µm Millipore filter 
(Millipore Corp., Bedford, MA).  
Preliminary experiments show that 2 days are sufficient for saturation of 
the micellar solutions to occur, and that the solubilized dyes do not adsorb 
to the membrane filters. 
Absorbance of each solution is measured at 483 nm (typical wavelength of 
Orange OT absorption) with Spectrophotometer (Wellwarm, Labsystems, 
Cambridge, UK).  
The CMC value is the intersection point between the line parallel to the 
abscissa through the first several points (reflecting the solubility of the dye 
at lower concentration of bile acid) and the line through the other points 
(when the dye solubilization increase). 
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3.3.4 Affinity binding to serum albumin 
 
Standard solution of each semi-synthetic bile acid is prepared dissolving 
about 11 mg (MW =400-500 u) in 500 µL of NaCl 0.15M to obtain a 50mM 
solution. For semi-synthetic BAs with carboxylic group in the side chain, 
salification is done with an excess of NaHCO3 (1:1, mol : mol). 
The percentage of affinity binding to serum albumin is evaluated by 
equilibrium dialysis at a fixed BA albumin ratio [31, 34, 36]. Each BA is 
dissolved at a concentration of 100 μM in a water solution with NaCl 
0.15M and 5% bovine serum albumin (BSA) fatty acid free, from Sigma 
Aldrich (St Louis, MO), and incubates for one day at room temperature.  
Two ml of this solution are placed in a cellulose membrane (cut-
off=12,000-14,000 Dalton), from Spectra/Por, Spectrum Medical lndustries 
lnc. (Los Angeles, CA) and then dialyzed against 25 ml of water solution 
with NaCl 0.15M (pH 7.20).  
The system is equilibrated by gently shaking for about three days at room 
temperature.  
The BA concentration of the dialyzed solutions (corresponding to the free 
unbound fraction) is determined with HPLC-ESI-MS/MS system for bile 
acids quantification, as reported below (in 3.4). 
The percentage of albumin binding is calculated with the ratio between 
initial BA concentration and the unbound concentration in the dialyzed 
fraction. 
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3.4 Bile fistula rat model experiments 
 
The In vivo experiments have been performed by Dr. Rita Aldini, 
Department of Pharmacy and Biotechnologies, University of Bologna. 
The procedure is conducted in Wistar-Han rats anesthetized: the bile duct 
was cannulated, and the BA was administered with intravenous (IV) or 
intraduodenal (ID) infusion [35].  
Each rat is subjected to one kind of infusion with one BA dose. 
For both the infusions, the dose of 1 µmol/min/kg is injected over 1 hour at 
2.5 ml/hour. The BA was dissolved in saline solution (NaCl 0.1M) for ID 
administration and in saline solution with 3% of albumin (BSA fatty acid 
free, Sigma Aldrich, MI, Italy) for IV administration. 
Bile and plasma were collected respectively at 15-minute and 30-minutes 
time intervals throughout the infusion and for the next two hours.  
BAs secretion and the following parameters have been calculated: bile 
flow (SVmax) gravimetrically, maximum secretion rate (SBmax) of the biliary 
secretion rate values over the 3 hours of bile collection, plasma 
concentration of BA and its metabolites over the three hours. 
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3.5 CCl4 induced cirrhosis rat model: Biodistribution experiments 
 
Experimental liver  cirrhosis has been  inducted in male Wistar-Han rats 
(Charles River Laboratories, Calco, LC, Italy), weighing 225-250 g, by one 
week phenobarbital (0.3 g.L−1 in drinking water) administration, Cirrhosis 
was induced by carbon tetrachloride (CCl4) inhalation [37].  
Phenobarbital was continued throughout the study as an enzyme induced. 
Animals are housed in a controlled environment (22–24°C), maintained on 
a standard 12-h light/dark cycle (lights on at 07.00 h) and had free access 
to food and water throughout the study. 
After one week exposure to phenobarbital, inhalation of CCl4 was started. 
The rats were placed in a gas chamber (70 × 25 × 30 cm) and 
compressed air, bubbling through a flask containing CCl4, was passed into 
the gas chamber via flow meter (1 L•min−1). Animals were exposed to the 
gas atmosphere twice a week (on Mondays and Fridays), starting with 0.5 
min of bubbling and 0.5 min in the gas atmosphere. Afterwards, the time 
was increased to 1 min and then by 1 min until 5 min of air flow and 5 min 
in gas atmosphere were reached. The mortality rate associated with this 
induction method was approximately 13%. The animals were fasted for 8 
hours before dosing.  
Then the rats were treated by oral administration (gavage, in conscious 
animals) of OCA at a dose of 30 mg/kg dissolved in 300 μL saline and 
immediately randomized. (Because animals were similar in weight, 
randomization was done after dose administration, to avoid any bias).  
Then the main organs (liver, kidneys, small intestine and colon tissue, 
small intestine and colon content, faeces), and fluids (plasma and urine) 
were collected after 1, 2, 4,8, 24 and 48 hours after the administration. 
OCA and its main metabolites have been quantified by the use of HPLC-
ES-MS/MS method previously reported. 
The same dose of OCA was administered to healthy rats and the same 
organs and fluids are collected after 24 and 48 hours in order to compare 
their biodistribution with that of cirrhotic rats.  
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3.6 BA and OCA extraction and clean-up from biological matrices 
 
3.6.1 Bile samples 
 
Rat bile samples are brought to room temperature and diluted 1:1000, 
(v/v) (bile samples from femoral infusion and from duodenal infusion in bile 
fistula rat model) with mobile phase used for HPLC method.  
The final solution is injected in the HPLC-ES-MS/MS system for BAs 
quantification, as reported below (in 3.4). 
When samples are out of the linearity range, they were diluted and 
reanalyzed [35]. 
 
3.6.2 Plasma and urine samples 
 
Plasma and urine samples (400 µl) with 10 µL of internal standard (mix 
1µM of OCA, T-OCA; mix 1µM of INT 777 ant T-INT 777 when the analyte 
is OCA) are diluted with 2mL of NaOH 0.1 N at 64°C for 30 minutes. The 
cartridge is conditioned before to sample loading.  
Plasma samples were loaded in the solid phase (SPE) C18 cartridge, 
previously conditioned with 5 ml of methanol and 5 ml of water, and then 
washed with 10 ml water.  
After that, the BAs  were eluted with 5 ml methanol, the eluate dried under 
vacuum, reconstituted with 100 µl of the mobile phase and injected into 
the HPLC-ES-MS/MS system for BAs quantification, as reported below (in 
3.4) [36]. 
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3.6.3 Liver and kidneys samples 
 
Liver and kidneys samples (0.5 g each), previously minutely chopped, 
were homogenized in 1 ml of phosphate buffer (0.005 M, pH 7.2) using a 
potter and then washed with methanol (3 × 0.5 mL).  
The mixture, was sonicated, vortexed, incubated at 37 °C for 20 minutes 
and centrifuged at 3000 rpm for 15 minutes.  
Four hundred µl of the supernatant with 10 µl of internal standard working 
was dried under vacuum and then reconstructed 2 ml of NaOH 0.1 N at 
64°C for 30 minutes. The SPE was carried out as shown above and the 
eluate is dried under vacuum, reconstituted with 100 µl of mobile phase 
and injected into the HPLC-ES-MS/MS system for BAs quantification, as 
reported below (in 3.4) [35]. 
 
3.6.4 Intestinal contents and faeces samples 
 
Small intestine, colon contents and faeces samples was minutely 
chopped, weighted (0.3 mg) and homogenized with 3mL of isopropyl 
alcohol using a mixer. The obtained mixture is vortexed and centrifuged at 
3000 rpm for 10 minutes. 
Ten µl of supernatant were diluted with 180 µl of mobile phase and 10 µl 
of internal standard (1:10 v/v dilution) with mobile phase and injected into 
the HPLC-ES-MS system for BAs quantification, as reported below (in 3.4) 
[35]. 
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4. Results and discussion 
 
4.1 Physico-Chemical properties  
 
The physico-chemical properties results for endogenous BAs and the first 
semi-synthetic analogues (i.e. INT 747, INT 777 and INT 767) were used 
as a reference to compare the structure-activity and metabolism with the 
new more recently synthesized analogues. The more relevant properties 
in aqueous solution refer to the acidity properties and to lipophilicity. 
 
4.1.1 pKa  
 
The pKa values measured in silico and the LogP values of each BA in the 
ionized form (A-) for the new semi-synthetic analogues are reported in 
Table 7. The Log P refers only to ionized species since the protonated one 
is often almost water insoluble and at the physiological pH the ionized is 
the predominant with the exception of the gastric acid content referring to 
the carboxylate BAs. 
About pKa, data shows that the 6α-ethyl substituted BAs maintain the 
same pKa of the endogenous analogues (CA and CDCA) and it is also true 
for the bioisosteres. 
However, the 23-fluorine substituted BAs have a pKa nearer the taurine 
conjugated analogues because the strong electronegativity of the fluorine 
atom allows to ionize easily the carboxylic group by electron windrowing 
effect. 
Moreover, as expected, the sulphates and sulphonate analogues have the 
same pKa of taurine conjugate endogenous BAs (i.e. TCDCA) being to 
fully ionized at all pH. 
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4.1.2 Lipophilicity 
 
The lipophilicity (LogPA
-) decreases by increasing the number of hydroxyl 
group in the steroid ring and also the nature of the substituents introduced 
in the side chain plays a major role. 
In the 6α-ethyl substituted group, UPF 2024 and UPF 2213 present  a 
negative LogPA
-, probably due to one more hydroxyl group in position 17β 
for the first and one methoxyl group in 23 position for the second in 
respect to UPF 2220 (Fig 10) 
 
 
 
 
 
 
 
 
 
 
Figure 10: structure differences between UPF 2220 and UPF 2024/UPF 2213 
 
These chemical modifications contribute to make these semi-synthetic 
BAs more hydrophilic than their analogues (CDCA, CA, INT 747).  
The same difference can be observed in the group of bioisosteres 
analogues between UPF 2225 and UPF 2295 and in the group of fluorine 
substituted between UPF 2207 and UPF 2304, because the first ones 
have one more hydroxyl group in 12α position (Fig 11). 
 
 
 
 
 
 
 
UPF-2220 
UPF-2024 
UPF-2213 
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Figure 11: structure differences between UPF 2295/UPF 2304 and 
UPF 2225/UPF 2207 
Moreover UPF 2220 is less lipophilic than its analogue INT 747 due to its 
shorter side chain (one methyl less). The same difference can be seen 
between INT 767 and UPF 2283 in the group of sulphates analogues. 
 
Table 7: pKa and LogPA
-
 values reported for the new semi-synthetic BAs and their 
main analogues 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BA pKa LogPA
- BA pKa LogPA
- 
CDCA 5 2.2±0.2 BIOISOSTERES 
TCDCA <1 0.9±0.1 UPF 2295 5.59 1.2±0.1 
CA 5 1.1±0.2 UPF 2308 5.71 2.0±0.3 
6α-ETHYL UPF 2289 5 1.9±0.2 
INT 747 5 2.5±0.4 UPF 2224 5.94 1.6±0.3 
INT 777 5 1.4±0.2 UPF 2225 5.59 1.5±0.3 
UPF 2024 5.29 -0.05±0.01 SULPHATE-SULPHONATE 
UPF 2220 5.24 1.3±0.3 INT 767 <1 2.0±0.2 
UPF 2213 4.36 -0.20±0.07 UPF 2284 <1 1.4±0.1 
FLUORIDE UPF 2307 <1 0.9±0.1 
UPF 2304 1.10 1.4±0.3 UPF 2293 <1 0.9±0.1 
UPF 2227 2.82 0.20±0.05 UPF 2283 <1 0.80±0.04 
UPF 2207 1.10 1.0±0.2 UPF 2021 <1 0.70±0.03 
UPF 2226 2.82 0.10±0.04 UPF 2023 <1 0.60±0.03 
UPF-2295 UPF-2225 
UPF-2304 UPF-2207 
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4.1.3 Water solubility 
 
The relationship with BA structure and presence of different substituents is 
not so directly evident since the solubility of a molecule is mostly related to 
the stability of the solid state crystalline structure and additional studies 
should be required starting from the measurement of the melting point. 
The water solubility data of the new semi-synthetic BAs and their main 
analogues are reported in Table 8.  
 
 
Table 8: Ws values, expressed in µM, reported for the new semi-synthetic BAs and 
their main analogues 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*hs=high solubility when value >1000µM 
 
These results shows that all the sulphates and sulphonates BAs have a 
high solubility (>1000µM), due to the full ionization in all the range of pH 
BA 
Ws 
(µM) 
BA 
Ws 
(µM) 
CDCA 32±4 BIOISOSTERES 
TCDCA hs* UPF 2295 135±9 
CA 273±10 UPF 2308 5±1 
6α-ETHYL UPF 2289 hs* 
INT 747 9±2 UPF 2224 392±11 
INT 777 99±3 UPF 2225 517±14 
UPF 2024 290±11 SULPHATE-SULPHONATE 
UPF 2220 75±4 INT 767 hs* 
UPF 2213 hs* UPF 2284 hs* 
FLUORIDE UPF 2307 hs* 
UPF 2304 16±2 UPF 2293 hs* 
UPF 2227 469±15 UPF 2283 hs* 
UPF 2207 225±10 UPF 2021 hs* 
UPF 2226 971±18 UPF 2023 hs* 
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from 0 to 12. About the carboxylic BAs, the water solubility at pH=1 was 
measured to ensure a complete protonation. As seen, the solubility 
decrease with the presence of 6α-ethyl in respect to the natural analogues 
CA and CDCA and on the contrary increase with the presence of more 
hydroxyl groups (UPF 2207 and UPF 2225 compared with UPF 2304 and 
UPF 2295) or fluorine atom (UPF 2227 compared with INT 777). 
 
4.1.4 Detergency 
 
The critical micellar concentrations (CMC) of new semi-synthetic BAs and 
their endogenous analogues are obtained from the plot concentration 
(mM) VS surface tension (ST) in Figure 12a and concentration (mM) vs 
absorbance (u.a.) in Figure 12b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: plot with surface tension (A) and absorbance (B) in respect to 
concentration (mM) of each BA 
 
A 
B 
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The CMC values for each BA and their calculated CMpH are reported in 
Table 9. 
 
Table 9: CMC values, expressed in mM, reported for the new semi-synthetic BAs 
and their main analogues 
 
*not detected **not calculated 
 
As shown, for the carboxylic BAs, the CMC increases with a decrease of 
side chain length and presence of substituents: when it is shorter (UPF 
2220 in respect to INT 747) or when it has fluorine substituent (UPF 2207 
and 2304 in respect to INT 777 and INT 747).  
This phenomenon is on line with the behavior of the classic anionic 
detergent in solution where the side chain play a role in the self-
aggregation of the lipophilic tail. [29] 
BA 
CMC 
(mM) 
CMpH BA 
CMC 
(mM) 
CMpH 
CDCA 3.2±0.9 7 BIOISOSTERES 
TCDCA 3±1 - UPF 2295 nd* nc** 
CA 9±2 6.5 UPF 2308 11±3 9.0 
6α-ETHYL UPF 2289 10±2 5.0 
INT 747 1.3±0.5 7.2 UPF 2224 5±1 7.0 
INT 777 2.0±0.7 6.1 UPF 2225 5±1 6.6 
UPF 2024 6.3±0.7 6.5 SULPHATE-SULPHONATE 
UPF 2220 10±2 7.1 INT 767 1.3±0.4 - 
UPF 2213 5±1 4.5 UPF 2284 3.0±0.6 - 
FLUORIDE UPF 2307 4.0±0.6 - 
UPF 2304 8.5±0.5 3.7 UPF 2293 5.0±0.7 - 
UPF 2227 3.9±0.6 3.9 UPF 2283 10±2 - 
UPF 2207 3.6±0.6 2.7 UPF 2021 6±1 - 
UPF 2226 6.0±0.9 3.6 UPF 2023 4.1±0.9 - 
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Concerning the bioisosteres, the higher CMC of UPF 2289 confirms the 
importance of the side chain length in BAs detergent properties. Moreover, 
the CMC for UPF 2295 cannot be measured due to its low solubility. 
Concerning the CMpH, i.e. the pH value above which a micellar phase 
dissolution is observed, it cannot be calculated for sulphates and 
sulphonates derivatives, as their endogenous analogues taurine 
conjugated (TCDCA) since their pKa cannot be calculated accurately and 
is very low. 
This is due to the fact that they are fully ionized (1>pH<12) and therefore 
their solubility is always higher than that of their free analogues and it 
doesn’t depend on micelles formation.   
 
4.1.4 Affinity binding to serum albumin  
 
The binding of the studied BAs has been performed at a fixed and defined 
initial BA concentration and excess of BSA (Bovine Serum Albumin). 
Therefore the obtained percentage of BA bound to albumin is not the 
thermodynamic value and therefore these data are only used for inter-
comparative studies. 
The measurement of the affinity constant (Kaff) requires studies with 
different initial concentrations and the data should be extrapolated by a 
Statchard plot [31, 36]. 
The results obtained for the percentage of albumin bound to each BA are 
reported in Table 10. 
The data show that there are no significant differences in affinity with 
albumin for the new synthetic BAs in respect to their endogenous 
analogues. 
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Table 10: Albumin binding values, expressed in %, reported for the new semi-
synthetic BAs and their main analogues 
 
 
4.2 Bile fistula rat model 
 
For each semi-synthetic BA, intraduodenal and intravenous acute 
administration experiments have been performed to obtain informations 
about bile flow, BA biliary secretion and simplified pharmacokinetic 
(plasma levels, hepatic and intestinal metabolism). 
 
 
 
 
 
 
BA 
Albumin binding 
(%) 
BA 
Albumine binding 
(%) 
CDCA 90±5 BIOISOSTERES 
TCDCA 76±2 UPF 2295 76±2 
CA 88±3 UPF 2308 90±5 
6α-ETHYL UPF 2289 99±5 
INT 747 96±5 UPF 2224 84±4 
INT 777 62±2 UPF 2225 83±4 
UPF 2024 47±1 SULPHATE-SULPHONATE 
UPF 2220 97±4 INT 767 85±4 
UPF 2213 55±2 UPF 2284 80±4 
FLUORIDE UPF 2307 86±5 
UPF 2304 66±2 UPF 2293 68±3 
UPF 2227 89±3 UPF 2283 45±1 
UPF 2207 99±4 UPF 2021 71±2 
UPF 2226 84±3 UPF 2023 74±2 
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4.2.1 Iv and id administration: bile flow and BA secretion, plasma levels 
 
Figure 13a shows a typical example of bile flow calculated by bile volume 
for each collected sample. The mean value of bile flow in control untreated 
animal in the pre-infusion period is about 40-60 µl/min/Kg: a cholestatic or 
choleretic effect can be observed depending on whether the maximum 
values measured is lower or higher than the above range.   
The Figure 13b reports the BA biliary secretion calculated from the 
expression:  
 
                 (  )              ( )            (  )
                (   )
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a)      (b) 
 
Figure 13: example of bile flow (a) and bile secretion (b) trends during each 
intraduodenal (blue) and intravenous (red) experiment (180 min) 
 
In Table 11 all the maximum secretory (SBAmax) and maximum bile flow 
(SVmax) are reported for each IV and ID experiment for each BA. 
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Table 11: SVmax (a) and SBAmax (b) in the intraduodenal (ID) and intravenous (IV) 
experiments 
  SVmax IV SVmax ID SBAmaxIV SBAmaxID 
 µl/min/kg µmol/min/kg 
UPF 2308 34±2 35±2 0.04±0.01 0.05±0.02 
UPF 2307 23±2 24±1 0.55±0.05 0.05±0.02 
UPF 2306 42±3 48±3 0.07±0.02 0.32±0.03 
UPF 2304 31±1 37±3 0.10±0.03 0.002±0.005 
UPF 2295 20±1 50±4 0.07±0.02 0.21±0.03 
UPF 2289 22±1 14±1 0.07±0.02 0.03±0.01 
UPF 2213 30±2 20±1 0.94±0.06 0.82±0.06 
UPF 2207 41±3 40±3 0.20±0.04 0.0010±0.0007 
UPF 2227 49±3 27±2 0.82±0.06 0.0010±0.0006 
UPF 2224 67±4 23±1 0.35±0.03 1.00±0.09 
UPF 2225 1.0±0.3 20±1 0.36±0.03 1.00±0.09 
UPF 2226 62±4 75±5 0.660.05 0.03±0.01 
UPF 2293 18±1 38±2 0.99±0.09 0.30±0.03 
UPF 2284 31±2 39±3 0.25±0.03 0.013±0.007 
UPF 2283 30±2 30±2 0.35±0.03 0.02±0.01 
UPF 2220 30±2 20±1 0.005±0.001 0.0010±0.0005 
UPF 2024 52±3 47±3 0.99±0.09 0.08±0.03 
UPF 2023 63±3 53±3 0.70±0.07 0.06±0.01 
UPF 2021 73±4 40±3 0.79±0.08 0.004±0.001 
INT 777 130±7 115±7 0.92±0.09 0.28±0.07 
INT 767 65±4 58±3 0.60±0.06 0.30±0.03 
INT 747 83±5 70±4 0.96±0.09 0.80±0.08 
TCDCA 41±3 44±3 0.63±0.06 0.08±0.01 
CDCA 63±4 65±4 0.98±0.08 0.90±0.06 
CA 105±6 90±5 1.00±0.08 0.85±0.08 
 
In Table 12 the mean maximum plasma concentration are reported for the 
ID experiment for each BA. 
 
 
 
 
 
 
 
 
55 
 
Table 12: maximum plasma concentration in the intraduodenal (ID) and 
experiments 
BA 
Plasma ID  
(µM) 
BA 
Plasma ID  
(µM) 
TCDCA 0.07±0.03 UPF 2308 1.2±0.1 
CDCA - UPF 2307 31±3 
CA - UPF 2306 6.2±0.6 
INT 777 0.20±0.07 UPF 2304 15±2 
INT 767 0.0010±0.0005 UPF 2295 2.9±0.3 
INT 747 0.010±0.007 UPF 2289 3.9±0.4 
UPF 2293 0.05±0.01 UPF 2213 59±3 
UPF 2284 1.9±0.4 UPF 2207 0.10±0.08 
UPF 2283 0.5±0.1 UPF 2227 9.9±1 
UPF 2220 85±4 UPF 2224 0.3±0.1 
UPF 2024 0.010±0.008 UPF 2225 6.3±0.6 
UPF 2023 1.6±0.3 UPF 2226 4.2±0.4 
UPF 2021 0.5±0.1   
 
 
BAs with a high SBAmax and a low plasma concentration (i.e. INT 747, 
UPF 2293) could be subjected to the enterohepatic circulation like natural 
occurring BA with a preferential distribution in the bile and small intestine. 
BAs with low SBAmax and a high plasma concentration (i.e. UPF 2220) 
could have systemic behavior and their plasma exposure will be 
responsible for the action in the organs involved. 
For BAs with low SBAmax and a low plasma concentration it can be 
hypothesized two different behaviors:  
- they could have a high intrahepatic concentration due to a relevant 
hepatic back diffusion to blood and poor biliary secretion, causing dose-
related potential hepatotoxicity/cytotoxicity) for the presence of high 
hepatic concentration (i.e. UPF 2213 and UPF 2304); 
- they could be gastrointestinal (GI) restricted, poorly absorbed either 
actively or passively by the intestine,  excreted with stool unmodified, like 
sulphate/sulphonate (i.e. UPF 2283 and UPF 2023) and taurine 
conjugated (i.e. UPF 2295) because of the less active intestinal transport 
for poor recognition by ileal transporters. 
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4.2.2 Hepatic and intestinal metabolism in vivo: identification of new 
metabolites 
 
In rat, semi-synthetic BAs are preferentially conjugated with taurine by the 
liver, as their natural analogues such as cholic and muricholic acid. 
Furthermore, during intraduodenal administration, the poorly absorbed 
BAs in the small intestine reach the terminal ileum and the colon where 
they are metabolized by the intestinal bacteria micro flora, and 
dehydroxylation, oxidation, epimerization process can be observed as 
indicated by their presence in stools. In the liver and small intestine 
conjugation with glucuronic acid or formation of sulphates at the hydroxyl 
groups or side chain carboxyl in order to produce more hydrophilic 
compounds better excreted with stools or urine  
These expected metabolites have been investigated and identified 
according to the m/z values thanks to HPLC-ES-MS/MS method 
previously described (see Table 13). 
Since the standards necessary for their precise quantification were not 
available, a calibration curve with more similar natural analogues is used.  
The  SBAmax values and plasma levels previously reported in Table 11 and 
12 are expressed including also metabolites concentration for each BA.  
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Table 13: main metabolites of natural bile acid hypothesized also for new semi-
synthetic BAs in bile 
 
METABOLITE m/z 
HPLC 
RETENTION 
TIME 
MS 
ACQUISITION 
MODE 
Epimer [M-H]-1 = [M-H]
-
0 tr1≠tr0 MRM/SIM 
Taurine 
[M-H]-0 +107 
 
tr1<tr0 MRM 
Glucuronide 
[M-H]-0 +176 
 
tr1<<tr0 MRM/SIM 
Sulphate 
[M-H]-0 +80 
 
tr1<<tr0 SIM 
Dehydroxylated 
[M-H]-0 -16 
- OH 
tr1>tr0 SIM 
Oxidized 
[M-H]-0 -2 
=O 
tr1>tr0 SIM 
 
In Figure 14 the main metabolism in bile for each new semi-synthetic BA is 
shown. 
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Figure 14: main metabolism of the new semi-synthetic BAs in bile 
 
These data demonstrate that the 6α-ethyl analogues with a carboxyl group 
in the side chain have a quite similar metabolism of the natural BAs, thus 
they undergo to taurine conjugation (i.e. INT 747), with the only exception 
that the ethyl in 6α position prevents the 7α-dehydroxylation and therefore 
increases the biological half-life time of the molecule by preventing this 
pathway by intestinal bacteria.  
Indeed, the presence of side chain substituents in C-23β position (fluorine 
or methyl) hinders the taurine conjugation process usually mediated by a 
CoA activation of the carboxyl which cannot be obtained by the presence 
of these C-23 substituents. This is the case of INT 777, UPF 2226, UPF 
2227, UPF 2213, UPF 2207 and UPF 2304). 
Moreover, for 23β mono-substituted it could be hypothesized an 
epimerization, that allow the taurine conjugation (INT 777 and its epimer 
with 23α methyl, UPF 2226 and its epimer UPF 2227).  
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The alternative pathway that increases their polarity and hydrophilicity is 
the conjugation with glucuronic acid, in order to be excreted with stools. 
The glucuronidation occurs probably in 3α position, because of 6α ethyl 
group reduces the reactivity of the 7α-OH not only for oxidation or 
dehydroxylation but also for conjugation with glucuronic acid.  
About the new analogues containing a sulphate/sulphonate group as a 
side chain, they are mostly secreted as such in bile and eliminated by 
urine or stools. The conjugation is not observed with the only exception of 
a low 3α-glucuronidation for more lipophilic analogues. Moreover In 
plasma, all semi-synthetic BAs are almost present only as such. 
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4.3 OCA in cirrhosis treatment: biodistribution and metabolism in vivo 
 
4.3.1 Induction of cirrhosis in rat  
 
After chronic inhalation of CCl4 according to the used protocol the rats 
show a moderate to severe cirrhosis with generalized fibrosis, periportal 
chronic inflammation, bile duct proliferation and destruction of normal liver 
architecture with the formation of regeneration nodules. In some rats it 
was associated to severe chronic hepatitis, i.e. the stage prior to the 
establishment of cirrhosis, in which there is considerable fibrosis and 
chronic inflammation, but without loss of the basic architecture to form 
nodules.  
A main difference between the CCl4 induced liver damage and human liver 
damage is that  the former is not immuno-mediated, but it is hepatotoxicity 
induced, spanning over a few weeks period and not over years, with little 
lymphocytic activation, but rather macrophages activation. However the 
functional and hemodynamic pattern is similar [38].  
The relative liver weight at the end of the induction period is increased in 
most of the animals, decreased in others, indicating in the latter group that 
the liver functional mass was greatly reduced. The great differences in 
liver weight (3, 6-16, 4 g) resemble the differences in humans. The liver 
weight increases by 50%, liver cells number increases and therefore it is 
possible that the different responses to Phenobarbital microsomal 
induction can be responsible for the highest liver weights observed. 
About plasma biomarkers, the CCl4 induced liver cirrhosis model provides 
a range of phenotypic expression of the liver disease, as it is the case with 
humans. Serum AST, ALT, and ALPK activities are changed significantly 
in rats; albumin is decreased from moderately to severely in about 75% of 
cases and plasma bilirubin is elevated in about 50% of cases. All the CCl4 
administered rats presented NH3 elevated levels, encephalopathy [39] and 
ascites (fluid accumulation in peritoneal cavity), from mild to severe. 
In addition, endogenous BA quali-quantitative composition in the studied 
biological fluids and organs have allowed to evaluate the consequence of 
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liver failure i.e. hepatic uptake and/or biliary secretion in their 
biodistribution and to compare data with OCA and its metabolites in 
cirrhotic and control animals (Figure 14). 
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Figure 14: endogenous BAs compared with OCA and its metabolites in healthy (□) 
and cirrhotic (○) rats after 24h 
 
Plasma total endogenous BAs are very high in comparison with controls: 
they were present free but also taurine conjugated. 
They are also high when plasma bilirubin levels are normal and in 
presence of normal liver parameters, but always associated with 
histological evidence of end stage liver disease.  
In the liver, endogenous BAs are present in concentrations similar to 
healthy rats, being both free and conjugated like in plasma.  
In the small intestine they are present free and conjugated with taurine; on 
the contrary in the colon they are present almost in free form.  
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In faeces, BAs are present in unconjugated form similarly in healthy and 
cirrhotic rats; in urines BAs free and taurine conjugated are present in 
higher concentrations in cirrhotic than in healthy rats. 
4.3.2 Identification of OCA metabolites  
 
The main metabolites identified and quantified with HPLC-ES-MS/MS 
method previously described are reported in Table 14. 
 
Table 14: parameters for identification and quantification of OCA and its main 
metabolites 
 
Compound 
tR  
(min.) 
Cone  
(V) 
Transition 
monitored (m/z) 
OCA 23.7 60 419419 
Tau-OC 22.5 90 526107 
Gly-OC 22.5 60 47674 
Glu-OC 4.6 40 595595 
3keto-OCA 25.3 60 418418 
 
 
4.3.3 Mass Balance in cirrhosis-induced rats 
 
From the amount (µmoles) of OCA and its metabolites recovered in the 
different organs and biological fluids analysed, a mass balance is 
calculated. This has been done after 24 and 48 hours from OCA 
administration, for which stools and urine samples were quantitatively 
collected (thanks to metabolic cages) and analysed. 
Mass balance is calculated in µmoles, extrapolating the total content in 
each organ/ fluid/ excrement (intestinal contents and faeces) from the 
concentration values and from the organ/ fluid/ excrement weight (or 
volume). Then the distribution (%) of OCA and its major metabolites is 
calculated and reported below.  
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Considering all the analysed metabolites, almost  94 % (Table 15) of the 
administered dose is recovered 24 hours after dosing and is distributed as 
reported in table 15 (numbers shown represent percentage of dose 
administered). 
 
Table 15: distribution % of OCA and its metabolites in cirrhotic rat after 24 h 
n.c.=not calculated (concentration less than LOQ) 
Sample OCA Tau-OCA Gly-OCA Glu-OCA 3keto-
OCA 
OCA TOT 
Plasma 0.13±0.01 0.5±0.1 0.008±0.001 0.6±0.1 n.c. 1.2±0.2 
Liver 0.36±0.1 18±6 19±7 2.4±0.9 n.c. 40±14 
Small intestine content 3±1 21±7 0.35±0.09 6.00±2 n.c. 31±10 
Colon content 7±3 0.04±0.02 0.09±0.05 n.c. 1.58±0.2 9±3 
Faeces 8±3 n.c. n.c. n.c. 0.75±0.3 9±3 
Urine 0.04±0.01 n.c. 0.04±0.02 4.4±0.7 n.c. 4.5±0.7 
Small intestine tissue n.c. n.c. n.c. n.c. n.c. n.c. 
Colon tissue n.c. n.c. n.c. n.c. n.c. n.c. 
Kidney n.c. n.c. n.c. n.c. n.c. n.c. 
Total 18±6 39±12 20±9 13±3 2.3±0.8 95 ± 31 
 
Considering all measured metabolites, up to 98 % (Table 16) of the 
administered dose is recovered 48 hours after dosing and is distributed as 
reported in table 16 (numbers shown represent percentage of dose 
administered). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
Table 16: distribution % of OCA and its metabolites in cirrhotic rat after 48 h 
n.c.=not calculated (concentration less than LOQ) 
Sample OCA Tau-OCA Gly-OCA Glu-OCA 3keto-
CA 
OCA  
TOT 
Plasma 0.1±0.1 0.10±0.05 0.05±0.01 0.05±0.01 n.c. 0.3±0.1 
Liver 0.3±0.1 8±1 12±3 1.4±0.4 n.c. 22±3 
Small intestine content 2±1 25±3 0.10±0.02 1.1±0.3 n.c. 28±4 
Colon content 7±1 0.10±0.05 0.20±0.03 n.c. 1.2±0.5 8±2 
Faeces 38±3 n.c. n.c. n.c. 1.2±0.5 39±5 
Urine n.c. 0.01± 0.010±0.001 n.c. n.c. 0.02±0.01 
Small intestine tissue n.c. n.c. n.c. n.c. n.c. n.c. 
Colon tissue n.c. n.c. n.c. n.c. n.c. n.c. 
Kidney n.c. n.c. n.c. n.c. n.c. n.c. 
Total  47±5 33±4 12±3 3±1 2±1 97±14 
 
The percent distribution of total OCA in the cirrhotic rats shows that OCA 
is more localized in the liver and to a less extent in the intestine in 
comparison with the one in control healthy rats (Tables 17 and 18). 
The percent recovered in blood is slightly higher than in control animals. 
This accounts for an impaired BA hepatic uptake which involves also OCA 
and/or biliary secretion that results in an increase of hepatic concentration 
and reduced in intestinal content.  
This distribution is similar to endogenous BAs, showing that OCA behaves 
very similar to common natural BAs. 
The overall body clearance from OCA is faster in healthy rats than in 
cirrhosis: in healthy rat, after 48 hours, 75% OCA is in faeces, while only 
42% is excreted in cirrhosis rats. OCA elimination by urines is present only 
in liver disease. The presence of OCA in plasma is associated with OCA 
higher elimination in urines. 
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Table 17: distribution % of OCA and its metabolites in healthy rat after 24 h n.c. 
=not calculated (concentration less than LOQ) 
Sample OCA Tau-
OCA 
Gly-
OCA 
Glu-
OCA 
3keto-
OCA 
OCA 
TOT 
Plasma 0.010 
±0.005 
n.c. n.c. n.c. n.c. 0.010 
±0.005 
Liver 0.2±0.
1 
9±2 12±3 1.3±0.8 n.c. 22±4 
Small intestine 
content 
0.3±0.
2 
47±6 n.c. n.c. n.c. 48±9 
Colon content 10±3 0.13 
±0.01 
0.17 
±0.06 
n.c. 1.6±0.2 11±2 
Faeces 2±1 n.c. n.c. n.c. 0.13±0.0
2 
2±1 
Urine n.c. n.c. n.c. n.c. n.c. n.c. 
Small intestine 
tissue 
n.c. n.c. n.c. n.c. n.c. n.c. 
Colon tissue n.c. n.c. n.c. n.c. n.c. n.c. 
Kidney n.c. n.c. n.c. n.c. n.c. n.c. 
Total  13±4 57±8 12±3 1.3±0.8 1.8±0.2 85±16 
 
 
 
Table 18: distribution % of OCA and its metabolites in healthy rat after 48 h 
n.c.=not calculated (concentration less than LOQ) 
Sample OCA Tau-
OCA 
Gly-
OCA 
Glu-
OCA 
3keto-
OCA 
OCA 
TOT 
Plasma 0.04 
±0.02 
n.c. n.c. n.c. n.c. 0.04 
±0.01 
Liver 0.10 
±0.05 
1.6±0.5 2.2±0.8 n.c. n.c. 3.9±2 
Small intestine 
content 
3.0±1 9±5 0.03 
±0.01 
0.35 
±0.06 
n.c. 12.28±4 
Colon content 4.0±3 0.09±0.0
3 
n.c. n.c. 1.3±0.
5 
5.41±3 
Faeces 62.2±1
0 
0.7±0.3 n.c. n.c. 2.7±0.
8 
65.6±13 
Urine n.c. n.c. n.c. n.c. n.c. n.c. 
Small intestine tissue n.c. n.c. n.c. n.c. n.c. n.c. 
Colon tissue n.c. n.c. n.c. n.c. n.c. n.c. 
Kidney n.c. n.c. n.c. n.c. n.c. n.c. 
Total  69±14 11±6 2.2±0.8 0.35 
±0.06 
4±1 87±22 
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5. Conclusions 
 
Previous studies on endogenous and semi-synthetic BAs analogues have 
demonstrated that small modifications in the chemical structure are able to 
significantly modify the physico-chemical properties and consequently 
their pharmacokinetics, metabolism including also FXR receptor activity. 
In particular the physico-chemical properties that properly define BA 
behavior in aqueous solutions and in biological fluids, allow to predict:  
- Drug formulation strategy regarding solubility in the gastric content (at 
low pH): water solubility of protonated species that should be enhanced if 
administered as protonated form ; BAs with a poor solubility could be 
modified for their solid state crystalline structure trying strategy to improve 
the solubility such as micronization or amorphization   
-Potential cytotoxicity due to modification of membrane structure by 
interaction and aggregation with lipids and proteins: detergency (critical 
micellar concentration, CMC); 
- Efficiency and mechanism of intestinal absorption through the enterocyte 
membrane (passive or active-carrier mediate), body fluid distribution and 
toxicity: lipophilicity (partition coefficient, LogPo/w):  
- Blood transport and hepatic uptake: albumin binding affinity (%) 
Analogues with a sulphate or sulphonate side chain head or carboxylate 
with a 23-substituent with electron withdrawing effect (fluorine or hydroxyl) 
are able to lower the pKa down to 2. They are always present in the body 
as organic anions and therefore never absorbed by the intestine by 
passive diffusion, even if relatively lipophilic with a LogP>1 and at all the 
physiological pH. 
BAs with a conventional side chain carboxyl group can be protonated at 
the enterocyte micro-environment and therefore absorbed by passive 
diffusion only if they are lipophilic (with a LogP>1.5-2). They are soluble 
only at a pH > 7 and when protonated (pH < 3), their solubility falls down 
and they are practically insoluble. 
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These changes in physico-chemical properties could lead to modify 
transport through the cells lipophilic membranes and therefore the 
intestinal absorption, the hepatic uptake and in general biodistribution and 
metabolism.  
Using , the in vivo experimental “bile fistula rat” model it was possible to 
evaluate by measuring the administered compound secreted in bile and 
simultaneously the plasma concentration the pharmacokinetic and 
metabolism of these compounds are therefore better definer the 
relationship between structure and pharmacokinetic  and  to classify these 
new compounds in three categories: 
 Enterohepatic: the analogues are efficiently absorbed when 
administered orally (id) either by active (through protein carrier) or 
passive (direct) mechanism and efficiently taken up by the liver from 
portal blood with a low spill-over in the systemic compartment. An 
efficient secretion in bile of the compounds or its hepatic metabolites 
(taurine conjugated) is associated with an efficient intestinal 
reabsorption and therefore an accumulation in the enterohepatic 
circulation with a minimal amount in the systemic circulation (less than 
10%) 
 Systemic: the analogues are absorbed when orally administered (id) 
and will be preferentially distributed in peripheral blood due to a 
relatively low hepatic uptake by the portal vein resulting in a consistent 
spill-over in the systemic compartment. Additionally a back diffusion 
from the liver could be involved. Metabolites should be excreted in 
stools and urine and poorly reabsorbed. 
 Intestinal restricted: poor absorbed when administered orally (id) for 
low lipophilicity or lack of active transporters. Soluble in the intestinal 
content and poorly metabolized by intestinal bacteria. 
As far as the CCl4 inhalation induced cirrhosis rat model this was 
developed to enter in more inside to the pharmacokinetic and metabolism 
of these molecules when used for the treatment of cholestatic liver disease 
where the liver functions is highly impaired. In the case of Obeticholic acid 
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(OCA), the animal model with hepatic decompensation due to cirrhosis 
induction is very useful to obtain more accurate and predictive 
informations, regarding its biodistribution and metabolism in human 
disease particularly excluding an excessive accumulation of the molecule 
in the liver.  
Despite the high variability of the data derived from the decompensated 
cirrhosis model, OCA behaves in term of biodistribution in the different 
organs almost like endogenous analogue CDCA having similar structure 
and physicochemical properties. 
The liver impairment caused by CCl4 inhalation  affect the endogenous 
BAs hepatic uptake and biliary secretion and on turn the hepatic 
metabolism of unconjugated BA to produce more hydrophilic taurine and 
glucuronide conjugates that facilitate their excretion from the liver in the 
bile or from  blood to urine. 
The relative high accumulation of OCA, like endogenous BAs, activates 
the conjugation metabolic pathway to form uncommon glycine (for rat) 
conjugate and glucuronide. This phenomenon is dose-response and 
different among animal species.  In human this will be less relevant in 
respect to rat because the endogenous BA pool is more lipophilic and 
therefore more tolerant to OCA. In addition, the glycine conjugation 
metabolism is predominant in respect to rat, where the endogenous BAs 
are almost conjugated with taurine.   
The percent recovery of the administered OCA and its main metabolites in 
the different organs is up to 95% after 24 hours and 97% after 48 hour 
from the oral administration. 
Moreover, the high OCA levels reflect the overall distribution of 
endogenous BAs pool in the systemic compartment as a result of the liver 
impairment caused by the CCl4. No selective or peculiar plasma levels 
have been observed. Similarly and expected behavior in the liver and 
small intestine. 
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The OCA administration could affect the endogenous BA pool qualitative 
composition since as expected the compound accumulate in the 
enterohepatic circulation like previous administered BAs (i.e. UDCA). 
Based on these overall conclusions, the collaboration project with Servier, 
Intercept Pharmaceutical and University of Perugia, proposes to continue 
these kind of analysis adding new rapid screening methods and cell 
models, using bio-chemiluminescence, to know the activity for FXR and 
TGR5 receptors of new synthetic bile acid. 
Furthermore an appropriate multivariate statistical analysis of the 
measured physico chemical properties and biodistribution parameters 
could be performed in order to create a predictive model for the 
physiological behavior of future semi-synthetic analogues. 
All these proposals could lead to design other new candidate analogues in 
order to discover promising novel drugs for the treatment of hepatic and 
metabolic disorders as PBC, NASH, obesity and diabetes, increasingly 
frequent in western countries. 
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